Carboxy-PTIO potassium

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

148819-94-7

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
50mg	电议
100mg	电议

产品介绍

Carboxy-PTIO potassium 是一种有效的一氧化氮 (NO) 清除剂，能与 NO 快速反应产生 NO₂。Carboxy-PTIO potassium 通过对脂多糖诱导大鼠模型中 NO 的直接清除作用，可预防低血压和内毒素休克。

生物活性

Carboxy-PTIO potassium is a potentnitric oxide (NO)scavenger that can make a quick reaction with NO to produce NO₂. Carboxy-PTIO potassium can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model^[1]^[2]^[3].

体外研究
(In Vitro)

Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) significantly suppresses the stimulation of NO expression induced by physalin A treatment, but no change is observed in Carboxy-PTIO treatment alone^[1].
Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) reduces physalin A-induced cleavage of procaspase-3 and PARP, down-regulated ICAD expression,diminishing DNA fragmentation in nuclei^[1].
Carboxy-PTIO potassium (200 μM; 1 h prior to physalin A; 24 hours) shows no effect on iNOS expression. However, decreased-mTOR and p-mTOR levels induced by physalin A is reversed by Carboxy-PTIO with concomitant suppression of LC3 I to LC3 II conversions in A375-S2 cells^[1].

Western Blot Analysis^[1]

Cell Line:	A375-S2 cells
Concentration:	200 μM
Incubation Time:	1 h prior to physalin A; 24 hours
Result:	Diminished physalin A-induced procaspase-3 and PARP cleavage.

体内研究
(In Vivo)

Carboxy-PTIO (intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min) treatment improves the hypotension, renal dysfunction and survival rate in Lps-treated rats. But it does not affect each parameter in naomal rats^[3].

Animal Model:	SD rats^[3]
Dosage:	0.056-1.70 mg/kg/min
Administration:	Intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min
Result:	Exhibited a potent therapeutic value in endotoxin shock through the direct scavenging action against NO.

分子量

315.39

性状

Solid

Formula

C₁₄H₁₆KN₂O₄

CAS 号

148819-94-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

H₂O : 25 mg/mL(79.27 mM;ultrasonic and warming and heat to 60℃)

DMSO : 10 mg/mL(31.71 mM;ultrasonic and warming and heat to 60℃)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	3.1707 mL	15.8534 mL	31.7068 mL
5 mM	0.6341 mL	3.1707 mL	6.3414 mL
10 mM	0.3171 mL	1.5853 mL	3.1707 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： PBS
Solubility: 50 mg/mL (158.53 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。